Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923321 | 0.90 | CYP2A13 (0.61) | SIGMAR1SMN1; SMN2GAACYP2A13ALDH1A1 | |
| SCHEMBL2926471 | 0.87 | SMN1; SMN2 (0.53) | SIGMAR1SMN1; SMN2GAAALDH1A1POLB | |
| Ammonia Solution, Strong SCHEMBL2930007 | 0.79 | SIGMAR1 (0.57) | SIGMAR1SMN1; SMN2CYP2A13ALDH1A1POLB | |
| SCHEMBL2931427 | 0.78 | HIF1A (0.61) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11511594 | 0.76 | FFAR1 (0.50) | GAAALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL11512272 | 0.75 | MAPT (0.56) | SMN1; SMN2GAAALDH1A1KDM4ETDP1 | |
| SCHEMBL24508364 | 0.74 | KDM4E (0.73) | SIGMAR1SMN1; SMN2CYP2A13ALDH1A1POLB | |
| SCHEMBL2927634 | 0.73 | CHRM1 (0.51) | SMN1; SMN2GAAALDH1A1KDM4EMAPT | |
| SCHEMBL30596611 | 0.73 | KDM4E (0.71) | SIGMAR1SMN1; SMN2CYP2A13ALDH1A1POLB | |
| SCHEMBL632217 | 0.73 | CHRM2 (0.55) | SMN1; SMN2GAAALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
| EP-2121616-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | Campiani, Giuseppe (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008101891-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | SIGMAR1 2671/4885SMN1; SMN2 4673/4885GAA 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.